A simple, easy to use, rapid, inexpensive, effective, point of care (POC) immunodiagnostic system for early confirmation of sepsis in at-risk patients is to be developed and validated. The biomarkers will include IL-6, C-reactive protein and soluble ICAM-1. These known biomarkers will be integrated via a new algorithm with other physical/clinical indicators, and refined using a unique bank of "sepsis-risk" patient samples and controls held within the consortium, before final clinical validation. Strong pilot data gained with the markers and the sample bank gives confidence in their utility and relevance. As well as universal threshold values for each analyte, the algorithm may also be based on sequential personalised values, determined using a low-cost reader (developed outside of the proposed project) to give more accurate readings. The assay is to be based on a simple multiplexed immunoassay platform already being developed by Mologic in a parallel TSB project due to finish in April 2012.

Benefiting from over 15 years extensive research, this collaboration between MaimoniDex, Mologic Ltd, Ig Innovations and Swansea University Medical School is working to develop a new biomarker for early diagnosis and confirmation of rheumatoid arthritis. MaimoniDex has identified a CDD44 isoform termed CD44vRA as a potential therapeutic target. The collaboration brings together the inventor, commercial diagnostic companies and access to patient samples and seeks to develop this biomarker as diagnostic blood test to aid, early diagnosis, early therapeutic intervention, therapeutic efficacy and clinical development of new therapies